The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

医学 美罗华 不利影响 内科学 脾切除术 随机对照试验 安慰剂 人口 外科 胃肠病学 淋巴瘤 环境卫生 病理 替代医学 脾脏
作者
Lamya Garabet,Pål André Holme,Bernadette Darné,Abderrahim Khélif,Tor Henrik Anderson Tvedt,Marc Michel,Waleed Ghanima
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 4892-4892 被引量:6
标识
DOI:10.1182/blood-2019-126974
摘要

Introduction Immune thrombocytopenia (ITP) is a disease characterized by low platelet count and increased risk of bleeding. However, there has been an increased focus on the risk of thromboembolism particularly venous thromboembolism (VTE) associated with ITP itself and with some of its therapies. Epidemiological studies have shown a doubling in the risk of VTE in ITP patients as compared to the general population. VTE has been reported with various ITP therapies including splenectomy, steroids, IVIG and thrombopoietin receptor agonists (TPO-RAs). In long-term studies on TPO-RAs, arterial and venous thrombosis occurred in 6% of treated patients. Rituximab, a monoclonal antibody directed against CD-20 on the B-cells is widely used as a treatment for ITP. It yields a response rate of 60% and is generally well-tolerated. However, to our knowledge VTE events following treatment with rituximab for ITP have not been reported. Aims We report thromboembolic adverse events encountered in 2 multicenter, randomized controlled trials (RCT) for adult ITP patients treated with rituximab: 1) Rituximab as second-line treatment for adult ITP (the RITP trial)(Ghanima et al, Lancet 2015; 385) and 2) The Rituximab Maintenance Therapy in ITP (The PROLONG Trial; NCT03010202) Methods RITP was a multicenter, randomized placebo-controlled trial in which adult patients with ITP unresponsive to corticosteroid and platelet count <30x10⁹/L were enrolled. Of the 112 ITP patients, 55 patients were randomly assigned to 4 weekly infusions of 375 mg/m2 rituximab and the remaining received placebo. Concurrent treatment with corticosteroids only was allowed during the study. The steroid dose had to be tapered to the lowest dose that kept the platelet count >20x10⁹/L. PROLONG is an ongoing multicenter, two-phase RCT. In the first phase, patients with ITP, who fail to achieve an adequate response to corticosteroids (prednisolone or dexamethasone) during the first year after diagnosis are randomized to receive rituximab 1000 mg twice with 15 days apart with or without dexamethasone 20 mg for 4 days starting with rituximab. In the secondphase, responding patients will be randomized at 24 weeks to maintenance therapy with 2 rituximab or placebo infusions separated by 24 weeks. Results Four venous thromboembolic events were reported in 4 patients: 2 of 55 patients who received rituximab in the RITP trial and 2 (one received dexamethasone+rituximab) of 52 patients included so far in the first phase of the PROLONG trial, which results in a VTE rate of 3.7% in the rituximab treated patients. No thromboembolic events were encountered in the placebo arm of the RITP study (n=54 patients, matched on age). Median time from treatment to event was 40.5 weeks, with 2 events occurring 7-14 weeks after the administration of the first dose of rituximab. Median platelet count at the time of VTE was 188x109/L. Characteristics of the 4 patients are shown in the table; none was splenectomized or received thrombopoietic agents before the VTE event. No arterial thromboembolic events were reported in the 2 trials. Conclusion The rate of VTE following treatment with rituximab in these 2 studies seems to be higher than what is expected in an adult ITP population and the general population (Norgaard et al. Br J Haematol. 2016;174). However, based on these results we cannot determine whether the venous thromboembolic events were just incidental events or triggered by the treatment and/or the normalization of platelet count or the presence of risk factors for VTE as old age and immobilization. Table Disclosures Tvedt: Ablynx, alexion and novartis: Consultancy. Michel:Novartis: Consultancy; Amgen: Consultancy; Rigel: Consultancy. Ghanima:Bayer: Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pfizer/BMS: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
慕遥的应助被净心采纳,获得10
1秒前
丘比特的应助被失眠孤兰采纳,获得10
1秒前
英姑的应助被失眠孤兰采纳,获得10
1秒前
2秒前
含蓄雨柏完成签到,获得积分10
2秒前
Nole的应助被严肃的梨采纳,获得10
2秒前
鸡血红发布了新的文献求助10
3秒前
4秒前
5秒前
海盗船长发布了新的文献求助10
5秒前
6秒前
幽默山槐完成签到,获得积分10
6秒前
6秒前
从容雅柏完成签到,获得积分10
6秒前
张顺完成签到,获得积分10
6秒前
不想科研的科研人完成签到,获得积分10
6秒前
7秒前
Sereilla完成签到,获得积分10
7秒前
Cherry完成签到 ,获得积分10
8秒前
lynyee关注了科研通微信公众号
8秒前
9秒前
123发布了新的文献求助10
9秒前
9秒前
爆米花的应助被无限之双采纳,获得10
9秒前
10秒前
10秒前
三斤鱼完成签到,获得积分10
10秒前
10秒前
不安晓曼发布了新的文献求助10
11秒前
11秒前
李之恒完成签到,获得积分10
12秒前
12秒前
13秒前
function发布了新的文献求助10
13秒前
13秒前
July0717_发布了新的文献求助10
14秒前
Hello的应助被Panda采纳,获得10
15秒前
15秒前
耶耶业发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128